nitrates has been researched along with Bright Disease in 11 studies
Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.
Bright Disease: A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.
| Excerpt | Relevance | Reference |
|---|---|---|
| "NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis." | 7.72 | NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis. ( Daig, U; Krämer, S; Liefeldt, L; Martini, S; Neumayer, HH; Peters, H; Rückert, M; Schäper, F, 2003) |
| " Here we assess the therapeutic effect of L-arginine supplementation, which has been shown to reduce fibrosis in a number of hypertensive models, given alone or in combination with low protein diet and started 24 hours after disease induction." | 7.70 | Tandem antifibrotic actions of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis. ( Border, WA; Noble, NA; Peters, H, 2000) |
| "NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis." | 3.72 | NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis. ( Daig, U; Krämer, S; Liefeldt, L; Martini, S; Neumayer, HH; Peters, H; Rückert, M; Schäper, F, 2003) |
| "To explore the effects of ligustrazine on proteinuria, urinary TxB2 (metabolism of thromboxane A2, TxA2) and 6-keto-PGF1alpha (metabolism of prostacyclines I2, PG I2), glomerular inducible nitric oxide(NO) synthase (iNOS) mRNA, urinary NO3-/NO2- (decomposing products of NO) and pathological changes in rats with passive Heymann nephritis (PHN)." | 3.72 | Inhibitory effects of ligustrazine, a modulator of thromboxane-prostacycline-nitric oxide balance, on renal injury in rats with passive Heyman nephritis. ( Dong, H; Tang, R; Tong, J; Wang, Y; Xu, J, 2004) |
| " Here we assess the therapeutic effect of L-arginine supplementation, which has been shown to reduce fibrosis in a number of hypertensive models, given alone or in combination with low protein diet and started 24 hours after disease induction." | 3.70 | Tandem antifibrotic actions of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis. ( Border, WA; Noble, NA; Peters, H, 2000) |
| " Oral administration of NG-monomethyl-L-arginine, a nitric oxide synthase inhibitor, prevented the development of glomerulonephritis and reduced the intensity of inflammatory arthritis in MRL-lpr/lpr mice." | 3.69 | The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally admi ( Gilkeson, GS; Granger, DL; Mason, SN; Misukonis, MA; Pippen, AM; Pisetsky, DS; Ruiz, P; Seldin, MF; Weinberg, JB; Wood, ER, 1994) |
| "Captopril treatment protected rats receiving L-NAME and none of the captopril-treated rats died." | 1.30 | Renoprotective effects of captopril in hypertension induced by nitric oxide synthase inhibition in experimental nephritis. ( Eriksson, A; Fyhrquist, F; Holthöfer, H; Miettinen, A; Tikkanen, I; Tikkanen, T; Törnroth, T; Uhlenius, N, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (45.45) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wagner, L | 1 |
| Riggleman, A | 1 |
| Erdely, A | 1 |
| Couser, W | 1 |
| Baylis, C | 1 |
| Ogawa, D | 1 |
| Shikata, K | 1 |
| Matsuda, M | 1 |
| Okada, S | 1 |
| Usui, H | 1 |
| Wada, J | 1 |
| Taniguchi, N | 1 |
| Makino, H | 1 |
| Peters, H | 2 |
| Daig, U | 1 |
| Martini, S | 1 |
| Rückert, M | 1 |
| Schäper, F | 1 |
| Liefeldt, L | 1 |
| Krämer, S | 1 |
| Neumayer, HH | 1 |
| Wang, Y | 1 |
| Tong, J | 1 |
| Tang, R | 1 |
| Dong, H | 1 |
| Xu, J | 1 |
| Weinberg, JB | 2 |
| Granger, DL | 1 |
| Pisetsky, DS | 1 |
| Seldin, MF | 1 |
| Misukonis, MA | 1 |
| Mason, SN | 1 |
| Pippen, AM | 1 |
| Ruiz, P | 1 |
| Wood, ER | 1 |
| Gilkeson, GS | 2 |
| Lianos, EA | 1 |
| Guglielmi, K | 1 |
| Sharma, M | 1 |
| Uhlenius, N | 1 |
| Tikkanen, T | 1 |
| Miettinen, A | 1 |
| Holthöfer, H | 1 |
| Törnroth, T | 1 |
| Eriksson, A | 1 |
| Fyhrquist, F | 1 |
| Tikkanen, I | 1 |
| Kakoki, M | 1 |
| Matsumoto, A | 1 |
| Nagata, D | 1 |
| Kobayakawa, N | 1 |
| Kimura, K | 1 |
| Momomura, S | 1 |
| Hirata, Y | 1 |
| Border, WA | 1 |
| Noble, NA | 1 |
| Keng, T | 1 |
| Privalle, CT | 1 |
| Sever, R | 1 |
| Cook, T | 1 |
| Cattell, V | 1 |
11 other studies available for nitrates and Bright Disease
| Article | Year |
|---|---|
Reduced nitric oxide synthase activity in rats with chronic renal disease due to glomerulonephritis.
Topics: Animals; Antibodies; Arginine; Autoantibodies; Blood Urea Nitrogen; Creatinine; Glomerulonephritis; | 2002 |
Protective effect of a novel and selective inhibitor of inducible nitric oxide synthase on experimental crescentic glomerulonephritis in WKY rats.
Topics: Amidines; Animals; Disease Progression; Enzyme Inhibitors; Glomerulonephritis; Heterocyclic Compound | 2002 |
NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis.
Topics: Animals; Arginine; Blood Pressure; Body Weight; Enzyme Inhibitors; Fibronectins; Fibrosis; Gene Expr | 2003 |
Inhibitory effects of ligustrazine, a modulator of thromboxane-prostacycline-nitric oxide balance, on renal injury in rats with passive Heyman nephritis.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Epoprostenol; Female; Fluorescent Antibody Technique, Direct; | 2004 |
The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally admi
Topics: Administration, Oral; Amino Acid Oxidoreductases; Animals; Arginine; Arthritis; Autoimmune Diseases; | 1994 |
Regulatory interactions between inducible nitric oxide synthase and eicosanoids in glomerular immune injury.
Topics: Animals; Base Sequence; Basement Membrane; Cyclooxygenase Inhibitors; Disease Models, Animal; DNA Pr | 1998 |
Renoprotective effects of captopril in hypertension induced by nitric oxide synthase inhibition in experimental nephritis.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Blood Pre | 1999 |
Analysis of nitric oxide in the exhaled air of patients with chronic glomerulonephritis.
Topics: Administration, Oral; Analysis of Variance; Anti-Inflammatory Agents; Case-Control Studies; Chronic | 1999 |
Tandem antifibrotic actions of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis.
Topics: Animals; Arginine; Culture Techniques; Dietary Proteins; Fibrosis; Glomerulonephritis; Kidney; Kidne | 2000 |
Peroxynitrite formation and decreased catalase activity in autoimmune MRL-lpr/lpr mice.
Topics: Animals; Arthritis; Autoimmune Diseases; Catalase; Cattle; DNA Damage; Glomerulonephritis; Immunoblo | 2000 |
Urinary excretion of nitrite and nitrate in experimental glomerulonephritis reflects systemic immune activation and not glomerular synthesis.
Topics: Animals; Glomerulonephritis; Kidney Glomerulus; Lipopolysaccharides; Macrophages; Male; Nitrates; Ni | 1992 |